[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:idh2-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"IDH2 Gene",26,23,[8,16,23,30,36,43,49,55,61,67,73,79,85,91,97,103,109,115,121,127,133,139,145,151,158,165],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05401097","IDH Targeted\u002FNon- Targeted vs Non-targeted\u002FIDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)",[12],"Phase 2","RECRUITING","2026-08-26T02:15:30.699880Z","2026-07-05T05:32:16.798999Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07215910","Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer",[20],"Phase 3","2026-08-26T02:18:03.638950Z","2026-06-17T02:29:30.057250Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07104799","Momelotinib During and After HCT in Myelofibrosis",[27],"Phase 1","2026-08-26T02:17:45.190188Z","2026-05-05T02:43:29.498826Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06672146","Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)",[12],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:29.296381Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT05588141","A Phase I\u002FII Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations",[40],"Phase 1\u002FPhase 2","2026-08-26T02:18:32.765187Z","2026-05-05T02:43:29.163159Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT06285890","Phase I Study of HC-7366 for Acute Myeloid Leukemia",[27],"2026-08-26T02:15:34.659160Z","2026-05-05T02:43:28.182174Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06577441","Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)",[12],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:27.989103Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06756308","A Study of Enasidenib in People With T-Cell Lymphoma",[12],"2026-08-03T02:37:16.921019Z","2026-05-05T02:43:27.511255Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT03728335","Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation",[12],"2026-08-03T03:27:21.703656Z","2026-05-05T02:43:27.399297Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05756777","A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)",[27],"2026-08-26T02:18:23.582895Z","2026-05-05T02:43:27.248629Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06240754","Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial",[12],"2026-08-26T02:17:11.311767Z","2026-05-05T02:43:27.133293Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07011004","A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia",[27],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:27.130925Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06666712","Chronic CED of TPT for Recurrent Malignant Glioma",[27],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:26.959232Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT06484062","Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes",[27],"2026-08-26T02:16:46.951087Z","2026-05-05T02:43:26.737999Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT04774393","Decitabine\u002FCedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",[40],"2026-08-26T02:16:23.080181Z","2026-05-05T02:35:31.777743Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT05873686","A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers",[27],"2026-08-26T02:17:00.709807Z","2026-07-19T19:36:05.121267Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT03418038","Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia",[12],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:29.732946Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT07209189","Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)",[12],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:28.214027Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT07270978","Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS",[27],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:27.951482Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT03383575","Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome",[12],"2026-08-26T02:15:25.633039Z","2026-05-05T02:43:26.928444Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT06176989","Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors",[12],"2026-08-26T02:17:21.315591Z","2026-06-16T05:54:07.915642Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[40],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT03683433","Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation",[12],"2026-08-26T02:15:43.339060Z","2026-04-29T02:57:57.075222Z",{"nct_id":152,"title":153,"phases":154,"status":155,"updated_at":156,"content_modified":157},"NCT07629089","VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and\u002For IDH2 Mutations",[27],"NOT_YET_RECRUITING","2026-08-26T02:16:44.178623Z","2026-06-06T00:48:49.532698Z",{"nct_id":159,"title":160,"phases":161,"status":162,"updated_at":163,"content_modified":164},"NCT06445907","Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia",[27],"ACTIVE_NOT_RECRUITING","2026-08-03T01:57:10.726985Z","2026-05-05T02:43:27.037954Z",{"nct_id":166,"title":167,"phases":168,"status":162,"updated_at":169,"content_modified":170},"NCT04550494","Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations",[12],"2026-08-03T03:54:23.387833Z","2026-05-05T02:43:29.385344Z"]